CN107397721B - 含有布比卡因的药物组合物及其制备方法和用途 - Google Patents
含有布比卡因的药物组合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN107397721B CN107397721B CN201610329869.XA CN201610329869A CN107397721B CN 107397721 B CN107397721 B CN 107397721B CN 201610329869 A CN201610329869 A CN 201610329869A CN 107397721 B CN107397721 B CN 107397721B
- Authority
- CN
- China
- Prior art keywords
- bupivacaine
- pharmaceutical composition
- nano particle
- pharmaceutically acceptable
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960003150 bupivacaine Drugs 0.000 title claims abstract description 99
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 title claims abstract description 91
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000002105 nanoparticle Substances 0.000 claims abstract description 62
- 239000000463 material Substances 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 239000000470 constituent Substances 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 64
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 20
- 238000002604 ultrasonography Methods 0.000 claims description 20
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 19
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000005406 washing Methods 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 14
- 229910001868 water Inorganic materials 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 11
- 230000003444 anaesthetic effect Effects 0.000 claims description 10
- 229920001610 polycaprolactone Polymers 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- HLHSUNWAPXINQU-GQCTYLIASA-N (E)-3-(3,4-dihydroxyphenyl)-N-prop-2-ynylprop-2-enamide Chemical compound OC=1C=C(C=CC=1O)/C=C/C(=O)NCC#C HLHSUNWAPXINQU-GQCTYLIASA-N 0.000 claims description 8
- 206010002091 Anaesthesia Diseases 0.000 claims description 8
- 230000037005 anaesthesia Effects 0.000 claims description 8
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 claims description 8
- 208000035823 Non-specific autoimmune cerebellar ataxia without characteristic antibodies Diseases 0.000 claims description 7
- 239000012876 carrier material Substances 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 4
- 239000003589 local anesthetic agent Substances 0.000 claims description 4
- 230000036407 pain Effects 0.000 claims description 4
- 230000002980 postoperative effect Effects 0.000 claims description 3
- 229940068984 polyvinyl alcohol Drugs 0.000 claims 4
- 150000002576 ketones Chemical class 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 27
- 229940079593 drug Drugs 0.000 abstract description 25
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 3
- 208000019622 heart disease Diseases 0.000 abstract description 2
- 230000002209 hydrophobic effect Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000013268 sustained release Methods 0.000 abstract description 2
- 239000012730 sustained-release form Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 238000005119 centrifugation Methods 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- -1 hydroxyl Bupivacaine Chemical compound 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 210000003594 spinal ganglia Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 239000004632 polycaprolactone Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000004626 polylactic acid Substances 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229960001050 bupivacaine hydrochloride Drugs 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 239000004633 polyglycolic acid Substances 0.000 description 3
- 229960004919 procaine Drugs 0.000 description 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- JCQBWMAWTUBARI-UHFFFAOYSA-N tert-butyl 3-ethenylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(C=C)C1 JCQBWMAWTUBARI-UHFFFAOYSA-N 0.000 description 3
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001448725 Endorchis Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940042577 exparel Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N n-hexyl alcohol Natural products CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- IJVRPNIWWODHHA-UHFFFAOYSA-N 2-cyanoprop-2-enoic acid Chemical compound OC(=O)C(=C)C#N IJVRPNIWWODHHA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- IGLKELDWPZFFKF-UHFFFAOYSA-N OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.P.P Chemical compound OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.P.P IGLKELDWPZFFKF-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
- LCAWNFIFMLXZPQ-UHFFFAOYSA-N ST055982 Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC=C(O)C=C2O1 LCAWNFIFMLXZPQ-UHFFFAOYSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 238000001838 alkalimetric titration Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- HUCIWBPMHXGLFM-UHFFFAOYSA-N bupivacaine hydrochloride hydrate Chemical compound O.[Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C HUCIWBPMHXGLFM-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000011208 chromatographic data Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000012549 congenital acardia Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- DZOKWSREAZGFFC-UHFFFAOYSA-N dehydrofukinone Natural products O=C1C(=C(C)C)CC2(C)C(C)CCCC2=C1 DZOKWSREAZGFFC-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 238000002692 epidural anesthesia Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000005250 spinal neuron Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610329869.XA CN107397721B (zh) | 2016-05-18 | 2016-05-18 | 含有布比卡因的药物组合物及其制备方法和用途 |
PCT/CN2017/077111 WO2017197970A1 (zh) | 2016-05-18 | 2017-03-17 | 含有布比卡因的药物组合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610329869.XA CN107397721B (zh) | 2016-05-18 | 2016-05-18 | 含有布比卡因的药物组合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107397721A CN107397721A (zh) | 2017-11-28 |
CN107397721B true CN107397721B (zh) | 2019-01-22 |
Family
ID=60324728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610329869.XA Active CN107397721B (zh) | 2016-05-18 | 2016-05-18 | 含有布比卡因的药物组合物及其制备方法和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN107397721B (zh) |
WO (1) | WO2017197970A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109316470A (zh) * | 2018-11-05 | 2019-02-12 | 中国医学科学院基础医学研究所 | 一种含有布比卡因的药物组合物及其制备方法和用途 |
CN116585488B (zh) * | 2023-05-08 | 2024-02-23 | 广东省第二人民医院(广东省卫生应急医院) | 一种罗哌卡因纳米载药材料及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3000462A1 (en) * | 2008-04-28 | 2016-03-30 | Zogenix, Inc. | Novel formulations for treatment of migraine |
CN101810908B (zh) * | 2009-02-25 | 2013-03-20 | 四川大学华西医院 | 局部麻醉药快速透皮给药系统 |
MX2015001194A (es) * | 2012-07-27 | 2015-11-23 | Izumi Technology Llc | Composiciones inhibidoras de eflujo y metodos de tratamiento que usan las mismas. |
CN104173322B (zh) * | 2014-09-16 | 2017-06-06 | 徐淑峰 | 一种含吡罗昔康的经皮吸收制剂及其制备方法 |
-
2016
- 2016-05-18 CN CN201610329869.XA patent/CN107397721B/zh active Active
-
2017
- 2017-03-17 WO PCT/CN2017/077111 patent/WO2017197970A1/zh active Application Filing
Non-Patent Citations (3)
Title |
---|
"局部麻醉用缓释盐酸布比卡因PLGA微球的制备及特性研究";钟延强,等;《第二军医大学学报》;20040831;第25卷(第8期);第865-868页 * |
"布比卡因聚乳酸缓释微球的制备及体外释药研究";俞媛,等;《第二军医大学学报》;20020131;第23卷(第1期);第87-89页 * |
"布比卡因脂质体的研究现状";周乐,等;《西南军医》;20130930;第15卷(第5期);第510-512页 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017197970A1 (zh) | 2017-11-23 |
CN107397721A (zh) | 2017-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2893922B1 (en) | Pharmaceutical formulations for the treatment of pulmonary arterial hypertension | |
EP3000463B1 (en) | Drug loaded microspheres for post-operative chronic pain | |
DE69333817T2 (de) | Leuprorelinpräparat mit verzögerter Wirkstoffabgabe | |
DE69730093T2 (de) | Zubereitung mit verzögerter Freisetzung | |
PT669128E (pt) | Micro-esfera de libertacao sustentada contendo antipsicoticos e processo para produzir a mesma | |
US20180021485A1 (en) | Method for manufacturing drug-containing biodegradable fiber material by electrospinning | |
CN106344521B (zh) | 一种高载药量可生物降解布比卡因微球的制备及其应用 | |
CN103703079A (zh) | 核-壳微球 | |
EP4233844A1 (en) | Naltrexone and risperidone combination sustained-release composition | |
CN101797239B (zh) | 马钱子总碱囊泡及其制备方法 | |
CN107335048A (zh) | 载促性腺激素释放激素类化合物缓释微球及其制备方法 | |
CN107397721B (zh) | 含有布比卡因的药物组合物及其制备方法和用途 | |
CN109758582B (zh) | 一种穿透血脑屏障的聚山梨酯80及其组分形成的载药胶束递送系统 | |
Guo et al. | Achieving long-acting local analgesia using an intelligent hydrogel encapsulated with drug and pH regulator | |
BR112020006893A2 (pt) | composições e métodos de taxano oral de alta resistência | |
US20140112957A1 (en) | Analegisic (Sebacoyl dinalbuphine ester) PLGA controlled release formulation form | |
JP6530480B2 (ja) | 微小インスリン、微小インスリン類似体及びそれらの製造方法 | |
JPH10203966A (ja) | 徐放性マイクロカプセルおよびその製造法 | |
CN109316470A (zh) | 一种含有布比卡因的药物组合物及其制备方法和用途 | |
Patel et al. | A review on PLGA based solvent induced in-situ forming implant | |
CN108815138B (zh) | 利培酮或其衍生物缓释微球、其制备方法及用途 | |
Shete | Microspheres as a Unique Drug Carrier for Controlled Drug Delivery: A Review | |
Çam et al. | Overview of Targeted Treatment Through Nano-Drug Delivery Systems and Controlled-Drug Release Systems | |
CN112870169B (zh) | 一种双载药环境敏感型口服Janus纳米粒及其制备方法和应用 | |
JP7470954B2 (ja) | ナノ粒子の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230628 Address after: No. 1200, Xinghai North Road, Taoyuan Street, Ninghai County, Ningbo City, Zhejiang Province Patentee after: Ningbo qizhinianhua Medical Technology Co.,Ltd. Address before: 100005 No. three, 5 Dongdan, Beijing, Dongcheng District Patentee before: INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: No. 1200, Xinghai North Road, Taoyuan Street, Ninghai County, Ningbo City, Zhejiang Province Patentee after: Korui Medical Technology (Ningbo) Co.,Ltd. Address before: No. 1200, Xinghai North Road, Taoyuan Street, Ninghai County, Ningbo City, Zhejiang Province Patentee before: Ningbo qizhinianhua Medical Technology Co.,Ltd. |